A trivalent, inactivated influenza vaccine (Vaxigrip®): summary of almost 50 years of experience and more than 1.8 billion doses distributed in over 120 countries
Introduction: Vaxigrip, a trivalent split-virion, inactivated vaccine available since 1968 has been in use longer than any other influenza vaccine. It is the most widely-used influenza vaccine, with more than 1.8 billion doses distributed in more than 120 countries. Areas covered: The significant bo...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2017-06-01
|
| Series: | Expert Review of Vaccines |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/14760584.2017.1324302 |
| _version_ | 1827813206750396416 |
|---|---|
| author | Margaret Haugh Viviane Gresset-Bourgeois Bérengère Macabeo Anne Woods Sandrine I. Samson |
| author_facet | Margaret Haugh Viviane Gresset-Bourgeois Bérengère Macabeo Anne Woods Sandrine I. Samson |
| author_sort | Margaret Haugh |
| collection | DOAJ |
| description | Introduction: Vaxigrip, a trivalent split-virion, inactivated vaccine available since 1968 has been in use longer than any other influenza vaccine. It is the most widely-used influenza vaccine, with more than 1.8 billion doses distributed in more than 120 countries. Areas covered: The significant body of evidence that confirms the efficacy, effectiveness, immunogenicity, and safety of Vaxigrip in healthy individuals of all ages and at-risk populations is summarized. The results from at least 15 randomized efficacy trials and 15 other studies have demonstrated that vaccination with Vaxigrip is efficacious against various clinical endpoints. It was estimated that more than 37 million laboratory-confirmed influenza episodes, 476,000 influenza-related hospitalizations, and 67,000 influenza-related deaths have been avoided by the more than 1.8 billion doses of Vaxigrip that have been distributed, emphasizing its important public health impact. Expert commentary: This strong evidence base in favor of Vaxigrip provides a robust foundation to support the implementation of the quadrivalent formulation. This quadrivalent formulation of Vaxigrip contains two A and two B influenza strains (VaxigripTetra), and has a similar immunogenicity and safety profile to the trivalent formulation while offering broader protection due to the addition of the second influenza B strain. |
| first_indexed | 2024-03-11T23:29:28Z |
| format | Article |
| id | doaj.art-1493da6bfeef453881ce20e733d1d80f |
| institution | Directory Open Access Journal |
| issn | 1476-0584 1744-8395 |
| language | English |
| last_indexed | 2024-03-11T23:29:28Z |
| publishDate | 2017-06-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Expert Review of Vaccines |
| spelling | doaj.art-1493da6bfeef453881ce20e733d1d80f2023-09-20T10:18:02ZengTaylor & Francis GroupExpert Review of Vaccines1476-05841744-83952017-06-0116654556410.1080/14760584.2017.13243021324302A trivalent, inactivated influenza vaccine (Vaxigrip®): summary of almost 50 years of experience and more than 1.8 billion doses distributed in over 120 countriesMargaret Haugh0Viviane Gresset-Bourgeois1Bérengère Macabeo2Anne Woods3Sandrine I. Samson4MediCom ConsultSanofi PasteurSanofi PasteurSanofi PasteurSanofi PasteurIntroduction: Vaxigrip, a trivalent split-virion, inactivated vaccine available since 1968 has been in use longer than any other influenza vaccine. It is the most widely-used influenza vaccine, with more than 1.8 billion doses distributed in more than 120 countries. Areas covered: The significant body of evidence that confirms the efficacy, effectiveness, immunogenicity, and safety of Vaxigrip in healthy individuals of all ages and at-risk populations is summarized. The results from at least 15 randomized efficacy trials and 15 other studies have demonstrated that vaccination with Vaxigrip is efficacious against various clinical endpoints. It was estimated that more than 37 million laboratory-confirmed influenza episodes, 476,000 influenza-related hospitalizations, and 67,000 influenza-related deaths have been avoided by the more than 1.8 billion doses of Vaxigrip that have been distributed, emphasizing its important public health impact. Expert commentary: This strong evidence base in favor of Vaxigrip provides a robust foundation to support the implementation of the quadrivalent formulation. This quadrivalent formulation of Vaxigrip contains two A and two B influenza strains (VaxigripTetra), and has a similar immunogenicity and safety profile to the trivalent formulation while offering broader protection due to the addition of the second influenza B strain.http://dx.doi.org/10.1080/14760584.2017.1324302seasonal influenzainfluenza vaccinetrivalent split-virion inactivated vaccinevaccine efficacyvaccine effectivenessvaccine immunogenicityvaccine reactogenicityvaccine safety |
| spellingShingle | Margaret Haugh Viviane Gresset-Bourgeois Bérengère Macabeo Anne Woods Sandrine I. Samson A trivalent, inactivated influenza vaccine (Vaxigrip®): summary of almost 50 years of experience and more than 1.8 billion doses distributed in over 120 countries Expert Review of Vaccines seasonal influenza influenza vaccine trivalent split-virion inactivated vaccine vaccine efficacy vaccine effectiveness vaccine immunogenicity vaccine reactogenicity vaccine safety |
| title | A trivalent, inactivated influenza vaccine (Vaxigrip®): summary of almost 50 years of experience and more than 1.8 billion doses distributed in over 120 countries |
| title_full | A trivalent, inactivated influenza vaccine (Vaxigrip®): summary of almost 50 years of experience and more than 1.8 billion doses distributed in over 120 countries |
| title_fullStr | A trivalent, inactivated influenza vaccine (Vaxigrip®): summary of almost 50 years of experience and more than 1.8 billion doses distributed in over 120 countries |
| title_full_unstemmed | A trivalent, inactivated influenza vaccine (Vaxigrip®): summary of almost 50 years of experience and more than 1.8 billion doses distributed in over 120 countries |
| title_short | A trivalent, inactivated influenza vaccine (Vaxigrip®): summary of almost 50 years of experience and more than 1.8 billion doses distributed in over 120 countries |
| title_sort | trivalent inactivated influenza vaccine vaxigrip r summary of almost 50 years of experience and more than 1 8 billion doses distributed in over 120 countries |
| topic | seasonal influenza influenza vaccine trivalent split-virion inactivated vaccine vaccine efficacy vaccine effectiveness vaccine immunogenicity vaccine reactogenicity vaccine safety |
| url | http://dx.doi.org/10.1080/14760584.2017.1324302 |
| work_keys_str_mv | AT margarethaugh atrivalentinactivatedinfluenzavaccinevaxigripsummaryofalmost50yearsofexperienceandmorethan18billiondosesdistributedinover120countries AT vivianegressetbourgeois atrivalentinactivatedinfluenzavaccinevaxigripsummaryofalmost50yearsofexperienceandmorethan18billiondosesdistributedinover120countries AT berengeremacabeo atrivalentinactivatedinfluenzavaccinevaxigripsummaryofalmost50yearsofexperienceandmorethan18billiondosesdistributedinover120countries AT annewoods atrivalentinactivatedinfluenzavaccinevaxigripsummaryofalmost50yearsofexperienceandmorethan18billiondosesdistributedinover120countries AT sandrineisamson atrivalentinactivatedinfluenzavaccinevaxigripsummaryofalmost50yearsofexperienceandmorethan18billiondosesdistributedinover120countries AT margarethaugh trivalentinactivatedinfluenzavaccinevaxigripsummaryofalmost50yearsofexperienceandmorethan18billiondosesdistributedinover120countries AT vivianegressetbourgeois trivalentinactivatedinfluenzavaccinevaxigripsummaryofalmost50yearsofexperienceandmorethan18billiondosesdistributedinover120countries AT berengeremacabeo trivalentinactivatedinfluenzavaccinevaxigripsummaryofalmost50yearsofexperienceandmorethan18billiondosesdistributedinover120countries AT annewoods trivalentinactivatedinfluenzavaccinevaxigripsummaryofalmost50yearsofexperienceandmorethan18billiondosesdistributedinover120countries AT sandrineisamson trivalentinactivatedinfluenzavaccinevaxigripsummaryofalmost50yearsofexperienceandmorethan18billiondosesdistributedinover120countries |